How to buy Keros Therapeutics stock | $38.14

Keros Therapeutics Inc is a biotechnology business based in the US. Keros Therapeutics shares (KROS) are listed on the NASDAQ and all prices are listed in US Dollars. Keros Therapeutics employs 44 staff and has a trailing 12-month revenue of around 0.00.

Keros Therapeutics stock price (NASDAQ: KROS)

Use our graph to track the performance of KROS stocks over time.

Keros Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$38.14
52-week range	$28.50 - $86.80
50-day moving average	$35.19
200-day moving average	$44.44
Wall St. target price	$86.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.41

Buy Keros Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Keros Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Keros Therapeutics price performance over time

Historical closes compared with the close of $38.14 from 2021-10-20

1 week (2021-10-14)	-4.22%
1 month (2021-09-22)	23.83%
3 months (2021-07-22)	0.63%
6 months (2021-04-22)	-39.48%

1 year (2020-10-21)	-26.85%
2 years (2019-10-18)	N/A
3 years (2018-10-18)	N/A
5 years (2016-10-18)	N/A

Keros Therapeutics financials

Revenue TTM	$100,000
Gross profit TTM	$-32,538,000
Return on assets TTM	-17.94%
Return on equity TTM	-28.76%
Profit margin	0%
Book value	$10.10
Market capitalisation	$909.9 million

TTM: trailing 12 months

Shorting Keros Therapeutics shares

There are currently 1.0 million Keros Therapeutics shares held short by investors – that's known as Keros Therapeutics's "short interest". This figure is 20.8% up from 855,034 last month.

There are a few different ways that this level of interest in shorting Keros Therapeutics shares can be evaluated.

Keros Therapeutics's "short interest ratio" (SIR)

Keros Therapeutics's "short interest ratio" (SIR) is the quantity of Keros Therapeutics shares currently shorted divided by the average quantity of Keros Therapeutics shares traded daily (recently around 291021.12676056). Keros Therapeutics's SIR currently stands at 3.55. In other words for every 100,000 Keros Therapeutics shares traded daily on the market, roughly 3550 shares are currently held short.

However Keros Therapeutics's short interest can also be evaluated against the total number of Keros Therapeutics shares, or, against the total number of tradable Keros Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Keros Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Keros Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0715% of the tradable shares (for every 100,000 tradable Keros Therapeutics shares, roughly 72 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Keros Therapeutics.

Find out more about how you can short Keros Therapeutics stock.

Keros Therapeutics share dividends

We're not expecting Keros Therapeutics to pay a dividend over the next 12 months.

Keros Therapeutics overview

Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

What percentage of Keros Therapeutics is owned by insiders or institutions?
Currently 14.639% of Keros Therapeutics shares are held by insiders and 81.473% by institutions. How many people work for Keros Therapeutics?
Latest data suggests 44 work at Keros Therapeutics. When does the fiscal year end for Keros Therapeutics?
Keros Therapeutics's fiscal year ends in December. Where is Keros Therapeutics based?
Keros Therapeutics's address is: 99 Hayden Avenue, Lexington, MA, United States, 02421 What is Keros Therapeutics's ISIN number?
Keros Therapeutics's international securities identification number is: US4923271013 What is Keros Therapeutics's CUSIP number?
Keros Therapeutics's Committee on Uniform Securities Identification Procedures number is: 492327101